Best Performing Stocks To Invest In 2018

Below is a quick look at S&P 500 sector performance so far in 2017. As shown, even after a pullback over the last week or so, Technology is still up double the S&P 500 with a gain of 34.2%. The next best sector is Financials with a gain of 19.1%, followed by Health Care (18.8%), Consumer Discretionary (18.5%), and Materials (18.4%). Telecom and Energy are both down 8%+ on the year.

Over the last two weeks, we’ve seen the year’s biggest winners take a beating, while investors have shifted a bit into value stocks that had been underperforming. Below is a list of the biggest losers in the Russell 1000 over the last two weeks. All of these stocks are down 10%+ over the last 10 trading days, and as you can see, there are quite a few of them!

Best Performing Stocks To Invest In 2018: PetMed Express, Inc.(PETS)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows Blue Buffalo Pet Products now roughly back up to its IPO close for retail investors while fresh pet food peer Freshpet Inc (NASDAQ: FRPT) is well below IPO levels and pet stocksCentral Garden & Pet Co (NASDAQ: CENT) andPetmed Express (NASDAQ: PETS) have been the best performers in the pet sector after PetSmart (NASDAQ: PETM) was acquired by a private equity group:

  • [By Peter Graham]

    Small cap pet stockPetmed Express Inc (NASDAQ: PETS) reportedQ2 earnings before the market opened this morning with shares soaring this morning as earnings were well beyond expectations. Net sales increased 10% to $66.7 million as new order sales increased 9% to $11.6 million while the Company’s online sales for the quarter ended September 30, 2017 were approximately 84% of all sales compared to 82% for the same quarter the prior year (with online sales increasing 12%). Net income was $8.8 million versusnet income of $4.9 million. The CEO commented:

  • [By Lisa Levin]

    Monday afternoon, the non-cyclical consumer goods & services shares surged 0.22 percent. Meanwhile, top gainers in the sector included Petmed Express Inc (NASDAQ: PETS), up 20 percent, and Kroger Co (NYSE: KR), up 3 percent.

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11
  • [By Peter Graham]

    A long term performance chart shows Blue Buffalo Pet Products roughly back up to its IPO close for retail investors while fresh pet food peer Freshpet Inc (NASDAQ: FRPT) isstill below IPO levels and pet stocksCentral Garden & Pet Co (NASDAQ: CENT) andPetmed Express (NASDAQ: PETS) have been much stronger performers in the pet sector after PetSmart (NASDAQ: PETM) was acquired by a private equity group:

Best Performing Stocks To Invest In 2018: Sanofi(SNY)

Advisors’ Opinion:

  • [By Emily Stewart]

    Paulson picked up 395,500 shares of Sanofi SA (SNY) valued at $16.6 million.

    Sanofi is a health care company engaged in the research, development, manufacture and marketing of healthcare products. It has a $101.4 billion market cap and trades at a P/E of 21.18. 

  • [By Stephen Mack]

    JNJ has recently made substantial investments in its pharmaceuticals pipeline. Most notably, in January the company beat Sanofi SA (NYSE: SNY) to buy a stake in Swiss drug company Actelion. The pairing is a perfect match, as it bulks up Johnson & Johnson’s pipeline, and gives Actelion the reach of a global powerhouse.

  • [By Brian Orelli]

    Image source: Getty Images.

    What happened with Alnylam Pharmaceuticals this quarter?
    All of the biotech’s revenue comes from its partners. The upfront payments are often amortized over many years, so the jump in revenue is nothing to get excited about. The big news during the quarter was the decision to stop development of revusiran after a phase 3 trial in patients with ATTR amyloidosis showed more patients taking revusiran died than those taking placebo. APOLLO, a phase 3 trial testing patisiran in patients with polyneuropathy due to hereditary ATTR amyloidosis, is due to read out in the middle of this year, hopefully leading to a marketing application filed with the FDA by the end of the year. Data presented for its hemophilia and other bleeding disorders drug, fitusiran, were positive, leading partner Sanofi (NYSE:SNY) to exercise its right to co-develop and co-promote fitusiran with Alnylam in the U.S., Canada, and Western Europe. Sanofi already had commercial rights to the rest of the world. The duo plans to start a phase 3 program for fitusiran in early 2017. The Medicines Company (NASDAQ:MDCO) presented more positive data for their cholesterol-lowering drug inclisiran, which was called ALN-PCSsc before Alnylam out-licensed the drug. The Medicines Company is running a new phase 2 trial in patients with a genetic disease that causes extremely high levels of cholesterol, and plans to start a phase 3 program in the middle of this year.

    What management had to say

    The APOLLO results, combined with starting phase 3 trials for fitusiran and inclisiran, puts Alnylam in a good position for years to come. CEO John Maraganore explained: “This potentially positions Alnylam to have a steady flow of phase 3 readouts, and if positive, commercial launches on essentially an annual basis going forward.”

Best Performing Stocks To Invest In 2018: Guaranty Bancorp(GBNK)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of PATRIOT FINANCIAL PARTNERS GP, LP’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=PATRIOT+FINANCIAL+PARTNERS+GP%2C+LP

    These are the top 5 holdings of PATRIOT FINANCIAL PARTNERS GP, LPBanc of California Inc (BANC) – 2,850,564 shares, 27.82% of the total portfolio. Guaranty Bancorp (GBNK) – 1,891,767 shares, 23.36% of the total portfolio. Shares reduced by 19.22%Meta Financial Group Inc (CASH) – 347,069 shares, 14.02% of the total portfolio. Sterling Bancorp (STL) – 1,048,980 shares, 11.07% of the total portfolio. Shares reduced by 16.01%MBT Financial Corp (MBTF) – 2,060,302 sha

Best Performing Stocks To Invest In 2018: Preferred Bank(PFBC)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Preferred Bank (PFBC) has surged 54% in the past year but still trades at a modest discount to the median S&P 1500 regional bank, based on both trailing earnings and estimated 2017 profits.

Leave a Reply

Your email address will not be published. Required fields are marked *